EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, MEI Pharma's enterprise value is $-27.13 Mil.
MEI Pharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $16.25 Mil. Therefore, MEI Pharma's EV-to-EBITDA for today is -1.67.
The historical rank and industry rank for MEI Pharma's EV-to-EBITDA or its related term are showing as below:
MEIP'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -25.21 Med: -1.6 Max: 27.23
Current: -1.67
During the past 13 years, the highest EV-to-EBITDA of MEI Pharma was 27.23. The lowest was -25.21. And the median was -1.60.
MEIP's EV-to-EBITDA is ranked better than 98.73% of 472
companies
in the Biotechnology industry
Industry Median: 9.1
vs MEIP: -1.67
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
MEI Pharma EV-to-EBITDA Historical Data
The historical data trend for MEI Pharma's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of MEI Pharma's EV-to-EBITDA
For the Biotechnology subindustry, MEI Pharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MEI Pharma's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MEI Pharma's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where MEI Pharma's EV-to-EBITDA falls into.
MEI Pharma EV-to-EBITDA Calculation
MEI Pharma's EV-to-EBITDA for today is calculated as:
MEI Pharma's current Enterprise Value is $-27.13 Mil.
MEI Pharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $16.25 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEI Pharma (NAS:MEIP) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
MEI Pharma's share price for today is $3.05.
MEI Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.970.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of MEI Pharma's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MEIP has been successfully added to your 